Merck & Co. Inc.’s decision to put one of the key cardiovascular drugs in its pipeline, MK-0524B, on hold indefinitely leaves the company – historically a leader in cardiovascular disease – with few offerings in development addressing this therapeutic area.
Although company executives have stated plans to keep cardiovascular drugs a priority, the company revealed through a filing with the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?